Pancreatic Islet Transplantation Technologies: State of the Art of Micro- and Macro-Encapsulation

被引：0
作者：
Cantarelli E. [1 ]
Citro A. [1 ]
Piemonti L. [1 ,2 ]
机构：
[1] Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan
[2] Vita- Salute University, Milan
来源：
Current Transplantation Reports | 2017年 / 4卷 / 3期
关键词：
Capsule immunoprotection; Device fibrotic reaction; Islet encapsulation; Islet transplantation; Type; 1; diabetes;
D O I：
10.1007/s40472-017-0154-9
中图分类号：
学科分类号：
摘要：
Purpose of Review: Type 1 diabetes (T1D) is an autoimmune disease characterized by the loss of insulin-producing cells in pancreatic islets. Despite islet transplantation is effective for selected T1D patients, its widespread application is limited by islet donor shortage and the need for lifelong immunosuppression. Micro- and macro-encapsulation aimed at enveloping cells in a perm-selective biocompatible membrane can potentially eliminate these limitations. This review summarizes tissue-engineering approaches tested in preclinical models of islet transplantation, highlighting technologies currently in the clinic. Recent Findings: More than 40 years of intensive research raised promises and challenges. Ongoing clinical studies have not yet achieved the desired success as obstacles remained to be overcome: deleterious fibrotic response toward the biomaterial, poor vascularization, insufficient oxygen delivery, and recipient’s immune reaction. Summary: Only the joint effort of bioengineering, cell biology, and immunology expertises will foster the development of novel, effective, and safe technologies for insulin-producing cell transplantation. © 2017, Springer International Publishing AG.
引用
收藏
页码：169 / 183
页数：14
相关论文
共 134 条
  • [1] Franklin V., Influences on technology use and efficacy in type 1 diabetes, J Diabetes Sci Technol., 10, 3, pp. 647-655, (2016)
  • [2] Deiss D., Adolfsson P., Alkemade-van Zomeren M., Bolli G.B., Charpentier G., Cobelli C., Et al., Insulin infusion set use: European perspectives and recommendations, Diabetes Technol Ther, 18, 9, pp. 517-524, (2016)
  • [3] Mannucci E., Monami M., Dicembrini I., Piselli A., Porta M., Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis, J Endocrinol Investig, 37, 5, pp. 477-495, (2014)
  • [4] Kovatchev B.P., Is glycemic variability important to assessing antidiabetes therapies?, Current diabetes reports, 6, 5, pp. 350-356, (2006)
  • [5] Shafiee G., Mohajeri-Tehrani M., Pajouhi M., Larijani B., The importance of hypoglycemia in diabetic patients, Journal of diabetes and metabolic disorders, 11, 1, (2012)
  • [6] Lind M., Svensson A.M., Kosiborod M., Gudbjornsdottir S., Pivodic A., Wedel H., Et al., Glycemic control and excess mortality in type 1 diabetes, N Engl J Med, 371, 21, pp. 1972-1982, (2014)
  • [7] Livingstone S.J., Levin D., Looker H.C., Lindsay R.S., Wild S.H., Joss N., Et al., Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010, JAMA, 313, 1, pp. 37-44, (2015)
  • [8] Vanstone M., Rewegan A., Brundisini F., Dejean D., Giacomini M., Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis, Ontario health technology assessment series, 15, 17, pp. 1-29, (2015)
  • [9] Alvarado-Martel D., Velasco R., Sanchez-Hernandez R.M., Carrillo A., Novoa F.J., Wagner A.M., Quality of life and type 1 diabetes: a study assessing patients’ perceptions and self-management needs, Patient preference and adherence, 9, pp. 1315-1323, (2015)
  • [10] Shapiro A.M., Ricordi C., Hering B.J., Auchincloss H., Lindblad R., Robertson R.P., Et al., International trial of the Edmonton protocol for islet transplantation, N Engl J Med, 355, 13, pp. 1318-1330, (2006)
12345678910